Cold pain therapy market is growing steadily
ReportsnReports.com adds the global cold pain therapy market is projected to reach USD 2.12 billion by 2023 from USD 1.69 billion in 2018, at a CAGR of 4.6%.
The increasing incidence of sports injuries and rising emphasis on exercise and gym activities, growing number of hip and knee surgeries across the globe and growing need for safer pain management modalities as opposed to oral drug therapy are expected to drive the demand for cold pain therapy products during the study period.
Browse 106 Market Data Tables and 126 Figures spread through 273 Pages and In-depth TOC on “Cold Pain Therapy Market by Product (OTC) (Gels, Sprays, Patches, Cold Packs, Wraps, Pads, and Roll-Ons), Prescription-Based (Motorized, Non-Motorized Devices), Applications (Musculoskeletal Disorders, Post-Operative Therapy, Sports Medicine, and Post-Trauma Therapy) – Global Forecast to 2023” here.
Some of the major players operating in the cold pain therapy market are Sanofi (France), DJO Finance (US), Pfizer (US), 3M (US), Hisamitsu Pharmaceutical (Japan), Johnson & Johnson (US), Medline Industries (US), Össur (Iceland), Performance Health (US), Beiersdorf (Germany), Rohto Pharmaceutical (US), Breg (US), Romsons Group of Industries (India), Custom Ice (US), and Unexo Life Sciences (India).